PTC Therapeutics (PTCT) Gets a Buy from Wells Fargo

Tip Ranks
2025.12.03 12:48
portai
I'm PortAI, I can summarize articles.

Wells Fargo analyst Tiago Fauth maintained a Buy rating on PTC Therapeutics with a price target of $93.00. Fauth, who focuses on the Healthcare sector, has an average return of 11.7% and a 49.59% success rate. Additionally, William Blair’s Sami Corwin also issued a Buy rating, while Goldman Sachs maintained a Sell rating on PTC Therapeutics.

Wells Fargo analyst Tiago Fauth maintained a Buy rating on PTC Therapeutics today and set a price target of $93.00.

TipRanks Cyber Monday Sale

  • Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
  • Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

Fauth covers the Healthcare sector, focusing on stocks such as BridgeBio Pharma, Insmed, and Alnylam Pharma. According to TipRanks, Fauth has an average return of 11.7% and a 49.59% success rate on recommended stocks.

In addition to Wells Fargo, PTC Therapeutics also received a Buy from William Blair’s Sami Corwin in a report issued today. However, on the same day, Goldman Sachs maintained a Sell rating on PTC Therapeutics (NASDAQ: PTCT).

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer